Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Guy

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Vaccine|July 26, 2016
Answer to the review from Halstead and Russell "Protective and immunological behavior of chimeric yellow fever dengue vaccine" (DOI 10.1016/j.vaccine.2016.02.004)Sri Rezki S Hadinegoro, Jose Luis Arredondo-García, Bruno Guy, et al.
Vaccine|February 10, 2015
Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccineJean Dubayle, Sandrine Vialle, Diane Schneider, et al.
Lancet (London, England)|October 19, 2016
Is discussion of dengue vaccination for the 2016 Olympics necessary?Jose L Arredondo-García, Sri R S Hadinegoro, Bruno Guy, et al.
Plos One|August 10, 2011
Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virusCharles E McGee, Konstantin A Tsetsarkin, Bruno Guy, et al.
Plos Neglected Tropical Diseases|July 27, 2016
Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy TrialsAnke Harenberg, Aymeric de Montfort, Frédérique Jantet-Blaudez, et al.
Vaccine|August 19, 2004
Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccineBruno Guy, Pornthep Chanthavanich, Sophie Gimenez, et al.
Vaccine|June 9, 2015
Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East AsiaIlaria Dorigatti, Ricardo Aguas, Christl A Donnelly, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|August 29, 2012
Evaluation of chimeric yellow fever 17D/dengue viral replication in ticksMária Kazimírová, Nathalie Mantel, Sandrine Raynaud, et al.
Plos One|June 6, 2019
Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adultsStéphane Pillet, Julie Couillard, Sonia Trépanier, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in MexicoGustavo H Dayan, Juan-Francisco Galán-Herrera, Remi Forrat, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Vaccine|July 26, 2016
Answer to the review from Halstead and Russell "Protective and immunological behavior of chimeric yellow fever dengue vaccine" (DOI 10.1016/j.vaccine.2016.02.004)Sri Rezki S Hadinegoro, Jose Luis Arredondo-García, Bruno Guy, et al.
Vaccine|February 10, 2015
Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccineJean Dubayle, Sandrine Vialle, Diane Schneider, et al.
Lancet (London, England)|October 19, 2016
Is discussion of dengue vaccination for the 2016 Olympics necessary?Jose L Arredondo-García, Sri R S Hadinegoro, Bruno Guy, et al.
Plos One|August 10, 2011
Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virusCharles E McGee, Konstantin A Tsetsarkin, Bruno Guy, et al.
Plos Neglected Tropical Diseases|July 27, 2016
Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy TrialsAnke Harenberg, Aymeric de Montfort, Frédérique Jantet-Blaudez, et al.
Vaccine|August 19, 2004
Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccineBruno Guy, Pornthep Chanthavanich, Sophie Gimenez, et al.
Vaccine|June 9, 2015
Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East AsiaIlaria Dorigatti, Ricardo Aguas, Christl A Donnelly, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|August 29, 2012
Evaluation of chimeric yellow fever 17D/dengue viral replication in ticksMária Kazimírová, Nathalie Mantel, Sandrine Raynaud, et al.
Plos One|June 6, 2019
Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adultsStéphane Pillet, Julie Couillard, Sonia Trépanier, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in MexicoGustavo H Dayan, Juan-Francisco Galán-Herrera, Remi Forrat, et al.
Pageof 6